MICHELLE PRICE: Open Payments
NPI 1992057111 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,623 in 169 payments from 25 companies in 2025. Trend: 2023 $2,625 · 2024 $3,034 · 2025 $3,623
Food & beverage: $3,624
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 33 | $642 |
| AstraZeneca Pharmaceuticals LP | 19 | $406 |
| Mallinckrodt Hospital Products Inc. | 14 | $315 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 11 | $257 |
| GENZYME CORPORATION | 11 | $255 |
| Grifols USA, LLC | 9 | $237 |
| Amgen Inc. | 15 | $225 |
| Regeneron Healthcare Solutions, Inc. | 8 | $189 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $171 |
| Merck Sharp & Dohme LLC | 7 | $143 |
Products named: DUPIXENT, TRELEGY ELLIPTA, ACTHAR, TEZSPIRE, NUCALA, Prolastin-C Liquid, OFEV, GLASSIA.
Industry payments across AL — which companies pay providers there.
